In particular, the SAFFRON study is evaluating the efficacy and safety of savolitinib in combination with osimertinib versus platinum-based doublet chemotherapy in patients with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed on treatment with osimertinib [86]. This evidence concerns the gene MET and non-small cell lung carcinoma.